Albitar Maher, Vose Julie M, Johnson Marcella M, Do Kim-Ann, Day Amanda, Jilani Iman, Kantarjian Hagop, Keating Michael, O'Brien Susan M, Verstovsek Srdan, Armitage James O, Giles Francis J
Quest Diagnostics Nichols Institute, 33608 Ortega Highway, Rm#108B, San Juan Capistrano, CA 92690-6130, United States.
Leuk Res. 2007 Feb;31(2):139-45. doi: 10.1016/j.leukres.2006.02.013. Epub 2006 Mar 20.
Plasma levels of beta-2 microglobulin (beta2M), a subunit of the human leukocyte antigen-class I (HLA-I) molecule, correlate negatively with outcome in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). We examined the clinical relevance of soluble HLA-I (sHLA-I) levels in NHL and HD. Sera from consecutive NHL (n=65) and HD (n=37) patients were analyzed in a blinded manner. NHL and HD patients had significantly higher levels of sHLA-1 and beta2M than control subjects. In NHL patients, sHLA-I levels correlated with clinical behavior in a fashion similar to that of beta2M. However, multivariate analysis incorporating beta2M, sHLA-I, and international prognostic index (IPI) indicated that NHL patients with elevated (>312.6mug/100mL) sHLA-I levels had significantly shorter survival, independent of IPI score as well as beta2M. In HD patients, beta2M but not sHLA-I levels were associated with clinical behavior. These findings not only establish the role of sHLA-I as an independent tumor marker in NHL that can be used to stratify patients, but also suggest that beta2M and sHLA-I may reflect different biological processes in HD and NHL. Further studies are needed to assess whether the immunomodulatory properties of sHLA-I may be responsible for its divergence from beta2M as an indicator of clinical behavior in HD.
β2微球蛋白（β2M）是人类白细胞抗原I类（HLA-I）分子的一个亚基，其血浆水平与非霍奇金淋巴瘤（NHL）和霍奇金病（HD）的预后呈负相关。我们研究了NHL和HD中可溶性HLA-I（sHLA-I）水平的临床相关性。对连续的NHL患者（n = 65）和HD患者（n = 37）的血清进行了盲法分析。NHL和HD患者的sHLA-1和β2M水平显著高于对照组。在NHL患者中，sHLA-I水平与临床行为的相关性与β2M相似。然而，纳入β2M、sHLA-I和国际预后指数（IPI）的多变量分析表明，sHLA-I水平升高（>312.6μg/100mL）的NHL患者生存期显著缩短，与IPI评分以及β2M无关。在HD患者中，与临床行为相关的是β2M水平而非sHLA-I水平。这些发现不仅确立了sHLA-I作为NHL中一种可用于对患者进行分层的独立肿瘤标志物的作用，还表明β2M和sHLA-I可能反映了HD和NHL中不同的生物学过程。需要进一步研究来评估sHLA-I的免疫调节特性是否可能是其在HD中作为临床行为指标与β2M存在差异的原因。
